Alto Neuroscience, Inc.
Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company developing treatments for neuropsychiatric conditions using its Precision Psychiatry Platform to identify biomarkers that may help predict patient response. The platform combines neurocognitive assessments, EEG, wearable-device, genetic… From the company’s description.
In fiscal 2025, Alto Neuroscience, Inc. reported a net loss of $63.24M. Operations used $51.77M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alto Neuroscience, Inc. does
In the company’s own words
Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company developing treatments for neuropsychiatric conditions using its Precision Psychiatry Platform to identify biomarkers that may help predict patient response. The platform combines neurocognitive assessments, EEG, wearable-device, genetic and genomic data with quantitative analytics, including machine learning. Its seven clinical-stage assets address major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia and Parkinson’s disease. Candidates include ALTO-207, a fixed-dose pramipexole and ondansetron combination for treatment-resistant depression; ALTO-300, an investigational antidepressant for biomarker-selected patients with major depressive disorder; and ALTO-101, a transdermal PDE4 inhibitor being studied for cognitive impairment associated with schizophrenia. Alto also develops candidates for bipolar depression and other indications. The company was founded in 2019 and acquired ALTO-207 and ALTO-208, a pramipexole and aprepitant combination for Parkinson’s disease, from Chase Therapeutics in 2025. Biomarker collection through its platform has involved more than 70 clinical sites and over 2,000 participants. Its website is https://www.altoneuroscience.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MOUNTAIN VIEW, CA
- Fiscal year end
- December
- CIK
- 1999480
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alto Neuroscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alto Neuroscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alto Neuroscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alto Neuroscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alto Neuroscience, Inc.'s last four quarterly filings that the numbers alone won't show?”